Skip to main content
Top
Published in: BMC Clinical Pathology 1/2012

Open Access 01-12-2012 | Research article

Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation

Authors: Atilla Kurt, Fatih Yanar, Oktar Asoglu, Emre Balik, Vakur Olgac, Hasan Karanlik, Sevda Tanrikulu Kucuk, Evin Ademoglu, Gulcin Yegen, Dursun Bugra

Published in: BMC Clinical Pathology | Issue 1/2012

Login to get access

Abstract

Background

The aim of this study was to evaluate apoptotic (Bcl-2, Bax expression, caspase-3 activity, and cytochrome-c) and angiogenic (MMP-9 levels and VEGF expression) markers in operable rectal cancer patients who were treated with preoperative chemoradiotherapy (CRT) followed by total mesorectal excision (TME). Understanding these factors will facilitate the identification of potential pathological responders before treatment, leading to better local control and survival rates.

Methods

Between March 2006 and March 2008, 29 patients withTNM Stage III (cT3 N+) mid or low rectal cancer were included in this study. Our sample consisted of 17 males (58.6%) and 12 females (41.4%). The median age was 60 years (range 24-88 years). Biopsy samples were taken from different portions of the tumors using flexible endoscopy before neoadjuvant CRT. Preoperatively, all patients received radiation (45-50.4 gray (Gy) in 25 cycles with concurrent 5-florouracil (5-FU) chemotherapy.

Results

A complete response was observed in 7 of 29 patients (24%). Bax staining was negative in 1 of the 7 patients (14%) in the pathological complete response (PCR) group and in 18 of the 22 patients (82%) in the no pathological complete response (noPCR) group (p = 0.001). MMP-9 and VEGF levels were higher in the noPCR group than the PCR group (p = 0.04, p = 0.05 respectively). No statistically significant differences were found between VEGF and MMP-9 levels in nodal downstaging. No statistically significant relationships were found between the other apoptotic factors (Bcl 2, cytochrome-c, and caspase-3 activity) and pathological response rate (p > 0.05).

Conclusion

In neoadjuvant CRT patients, high levels of Bax expression and low levels of VEGF and MMP-9 expression on preoperative biopsies indicate that the patient will potentially be a good pathological responder.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hawk ET, Linburg PJ, Viner JL: Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002, 82: 905-941. 10.1016/S0039-6109(02)00046-4.CrossRefPubMed Hawk ET, Linburg PJ, Viner JL: Epidemiology and prevention of colorectal cancer. Surg Clin North Am. 2002, 82: 905-941. 10.1016/S0039-6109(02)00046-4.CrossRefPubMed
2.
go back to reference Medich D, McGinty J, Parda D: Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum. 2001, 44: 1123-1128. 10.1007/BF02234632.CrossRefPubMed Medich D, McGinty J, Parda D: Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum. 2001, 44: 1123-1128. 10.1007/BF02234632.CrossRefPubMed
3.
go back to reference Ruo L, Tickoo S, Klimstra DS: Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002, 236: 75-81. 10.1097/00000658-200207000-00012.CrossRefPubMedPubMedCentral Ruo L, Tickoo S, Klimstra DS: Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002, 236: 75-81. 10.1097/00000658-200207000-00012.CrossRefPubMedPubMedCentral
4.
go back to reference Valentini V, Coco C, Picciocchi A: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002, 53: 664-674. 10.1016/S0360-3016(02)02764-5.CrossRefPubMed Valentini V, Coco C, Picciocchi A: Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys. 2002, 53: 664-674. 10.1016/S0360-3016(02)02764-5.CrossRefPubMed
5.
go back to reference Reerink O, Karrenbeld A, Plukker JT: Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res. 2004, 24: 1217-1221.PubMed Reerink O, Karrenbeld A, Plukker JT: Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res. 2004, 24: 1217-1221.PubMed
6.
go back to reference Theodoropoulos G, Wise WE, Padmanabhan A: T level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002, 45: 895-903. 10.1007/s10350-004-6325-7.CrossRefPubMed Theodoropoulos G, Wise WE, Padmanabhan A: T level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum. 2002, 45: 895-903. 10.1007/s10350-004-6325-7.CrossRefPubMed
7.
go back to reference Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P: Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002, 94: 1121-1130. 10.1002/cncr.10327.CrossRefPubMed Bouzourene H, Bosman FT, Seelentag W, Matter M, Coucke P: Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer. 2002, 94: 1121-1130. 10.1002/cncr.10327.CrossRefPubMed
8.
go back to reference Wheeler JM, Dodds E, Warren BF: Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum. 2004, 47: 2025-2031. 10.1007/s10350-004-0713-x.CrossRefPubMed Wheeler JM, Dodds E, Warren BF: Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. Dis Colon Rectum. 2004, 47: 2025-2031. 10.1007/s10350-004-0713-x.CrossRefPubMed
9.
go back to reference Ammann K, Kirchmayr W, Klaus A: Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum. Arch Surg. 2003, 138: 257-261. 10.1001/archsurg.138.3.257.CrossRefPubMed Ammann K, Kirchmayr W, Klaus A: Impact of neoadjuvant chemoradiation on anal sphincter function in patients with carcinoma of the midrectum and low rectum. Arch Surg. 2003, 138: 257-261. 10.1001/archsurg.138.3.257.CrossRefPubMed
10.
go back to reference Marijnen CA, Van de Velde CJ, Putter H: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005, 23: 1847-1858. 10.1200/JCO.2005.05.256.CrossRefPubMed Marijnen CA, Van de Velde CJ, Putter H: Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005, 23: 1847-1858. 10.1200/JCO.2005.05.256.CrossRefPubMed
11.
go back to reference Peeters KC, van de Velde CJ, Leer JW: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients. J Clin Oncol. 2005, 23: 6199-6206. 10.1200/JCO.2005.14.779.CrossRefPubMed Peeters KC, van de Velde CJ, Leer JW: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients. J Clin Oncol. 2005, 23: 6199-6206. 10.1200/JCO.2005.14.779.CrossRefPubMed
12.
go back to reference Birgisson H, Pahlman L, Gunnarsson U, Glimelius B: Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005, 23: 6126-6131. 10.1200/JCO.2005.02.543.CrossRefPubMed Birgisson H, Pahlman L, Gunnarsson U, Glimelius B: Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005, 23: 6126-6131. 10.1200/JCO.2005.02.543.CrossRefPubMed
13.
go back to reference Ward RL, Todd AV, Santiago F, O’Connor T, Hawkins NJ: Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer. 1997, 79: 1106-1113. 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D.CrossRefPubMed Ward RL, Todd AV, Santiago F, O’Connor T, Hawkins NJ: Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer. 1997, 79: 1106-1113. 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D.CrossRefPubMed
14.
go back to reference Bedi A, Pasricha P, Akhtar AJ: Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995, 55: 1811-1816.PubMed Bedi A, Pasricha P, Akhtar AJ: Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995, 55: 1811-1816.PubMed
15.
go back to reference Hashimoto S, Koji T, Kohara N, Kanematsu T, Nakane P: Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. Virchow Arch. 1997, 431: 241-248. 10.1007/s004280050095.CrossRef Hashimoto S, Koji T, Kohara N, Kanematsu T, Nakane P: Frequency of apoptosis relates inversely to invasiveness and metastatic activity in human colorectal cancer. Virchow Arch. 1997, 431: 241-248. 10.1007/s004280050095.CrossRef
16.
go back to reference Spilsbury K, Garret K, Shen WY, Costable IJ, Rakoczy PE: Overexpression of vascular endothelial growth factor (VEGF) in the retinal epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000, 157: 135-143. 10.1016/S0002-9440(10)64525-7.CrossRefPubMedPubMedCentral Spilsbury K, Garret K, Shen WY, Costable IJ, Rakoczy PE: Overexpression of vascular endothelial growth factor (VEGF) in the retinal epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000, 157: 135-143. 10.1016/S0002-9440(10)64525-7.CrossRefPubMedPubMedCentral
17.
go back to reference Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ: Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006, 32: 55-64. 10.1016/j.ejso.2005.09.010.CrossRefPubMed Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ: Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006, 32: 55-64. 10.1016/j.ejso.2005.09.010.CrossRefPubMed
18.
go back to reference Heald RJ: Total mesorectal excision (TME). Acta Chir Iugosl. 2000, 47: 17-18.PubMed Heald RJ: Total mesorectal excision (TME). Acta Chir Iugosl. 2000, 47: 17-18.PubMed
19.
go back to reference Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical excision. Histopathological study of lateral tumor spread and surgical excision. Lancet. 1986, 2: 996-999.CrossRefPubMed Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical excision. Histopathological study of lateral tumor spread and surgical excision. Lancet. 1986, 2: 996-999.CrossRefPubMed
20.
go back to reference Greene FL, Page DL, Fleming ID: AJCC Cancer Staging Manual. 2002, New York: Springer, 6CrossRef Greene FL, Page DL, Fleming ID: AJCC Cancer Staging Manual. 2002, New York: Springer, 6CrossRef
21.
go back to reference Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997, 12: 19-23. 10.1007/s003840050072.CrossRefPubMed Dworak O, Keilholz L, Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997, 12: 19-23. 10.1007/s003840050072.CrossRefPubMed
22.
go back to reference Navarro M, Dotor E, Rivera F: A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006, 66: 201-205. 10.1016/j.ijrobp.2006.04.007.CrossRefPubMed Navarro M, Dotor E, Rivera F: A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2006, 66: 201-205. 10.1016/j.ijrobp.2006.04.007.CrossRefPubMed
23.
go back to reference Spitz FR, Giacco GG, Hess K: p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997, 3: 1685-1690.PubMed Spitz FR, Giacco GG, Hess K: p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res. 1997, 3: 1685-1690.PubMed
24.
go back to reference Fu CG, Tominaga O, Nagawa H: Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum. 1998, 41: 68-74. 10.1007/BF02236898.CrossRefPubMed Fu CG, Tominaga O, Nagawa H: Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum. 1998, 41: 68-74. 10.1007/BF02236898.CrossRefPubMed
25.
go back to reference Saw RP, Morgan M, Koorey D: p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum. 2003, 46: 192-202. 10.1007/s10350-004-6524-2.CrossRefPubMed Saw RP, Morgan M, Koorey D: p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum. 2003, 46: 192-202. 10.1007/s10350-004-6524-2.CrossRefPubMed
26.
go back to reference Rau B, Sturm I, Lage H: Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol. 2003, 21: 3391-3401. 10.1200/JCO.2003.07.077.CrossRefPubMed Rau B, Sturm I, Lage H: Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol. 2003, 21: 3391-3401. 10.1200/JCO.2003.07.077.CrossRefPubMed
27.
go back to reference Sogawa N, Takiguchi N, Koda K: Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy. Int J Oncol. 2002, 21: 787-793.PubMed Sogawa N, Takiguchi N, Koda K: Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy. Int J Oncol. 2002, 21: 787-793.PubMed
28.
go back to reference Scopa CD, Vagianos C, Kardamakis D, Kalofonos HP, Batistatou A, Vagianos C: Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol. 2001, 9: 329-334. 10.1097/00022744-200112000-00007.PubMed Scopa CD, Vagianos C, Kardamakis D, Kalofonos HP, Batistatou A, Vagianos C: Bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol. 2001, 9: 329-334. 10.1097/00022744-200112000-00007.PubMed
29.
go back to reference Diez M, Ramos P, Medrano MJ: Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology. 2003, 64: 213-219. 10.1159/000069307.CrossRefPubMed Diez M, Ramos P, Medrano MJ: Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology. 2003, 64: 213-219. 10.1159/000069307.CrossRefPubMed
30.
go back to reference Aschele C, Lonardi S, Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev. 2002, 28: 27-47. 10.1053/ctrv.2002.0253.CrossRefPubMed Aschele C, Lonardi S, Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev. 2002, 28: 27-47. 10.1053/ctrv.2002.0253.CrossRefPubMed
31.
go back to reference Komuro Y, Watanabe T, Hosoi Y: The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer. 2002, 95: 1199-1205. 10.1002/cncr.10807.CrossRefPubMed Komuro Y, Watanabe T, Hosoi Y: The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer. 2002, 95: 1199-1205. 10.1002/cncr.10807.CrossRefPubMed
32.
go back to reference Garcia-Aguilar J, Chen Z, Smith DD: Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2001, 254: 486-493.CrossRef Garcia-Aguilar J, Chen Z, Smith DD: Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2001, 254: 486-493.CrossRef
33.
go back to reference Scopa CD, Tsamandas AC, Zolo Kalofonos HP, Batistatou A, Vagianos C: The potential role of bcl-2 and Ki67 expression and apoptosis in colorectal carcinoma. A clinicopathologic study. Dig Dis Sci. 2003, 48: 1990-1997. 10.1023/A:1026178506348.CrossRefPubMed Scopa CD, Tsamandas AC, Zolo Kalofonos HP, Batistatou A, Vagianos C: The potential role of bcl-2 and Ki67 expression and apoptosis in colorectal carcinoma. A clinicopathologic study. Dig Dis Sci. 2003, 48: 1990-1997. 10.1023/A:1026178506348.CrossRefPubMed
34.
go back to reference Chang HJ, Jung KH, Kim DY: Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005, 36: 364-371. 10.1016/j.humpath.2005.01.018.CrossRefPubMed Chang HJ, Jung KH, Kim DY: Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005, 36: 364-371. 10.1016/j.humpath.2005.01.018.CrossRefPubMed
35.
go back to reference Tsamandas AC, Kardamakis D, Petsas T: Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients’ outcome. In Vivo. 2007, 21: 113-118.PubMed Tsamandas AC, Kardamakis D, Petsas T: Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients’ outcome. In Vivo. 2007, 21: 113-118.PubMed
36.
go back to reference Nehls O, Okech T, Hsieh CJ: Low Bax protein expression corralates with disease recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys. 2005, 61: 85-91. 10.1016/j.ijrobp.2004.05.023.CrossRefPubMed Nehls O, Okech T, Hsieh CJ: Low Bax protein expression corralates with disease recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys. 2005, 61: 85-91. 10.1016/j.ijrobp.2004.05.023.CrossRefPubMed
37.
go back to reference Brown JM, Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005, 5: 231-237. 10.1038/nrc1560.PubMed Brown JM, Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer. 2005, 5: 231-237. 10.1038/nrc1560.PubMed
38.
go back to reference De Heer P, De Bruin EC, Klein-Kranenbarg E: Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res. 2007, 13: 5810-5815. 10.1158/1078-0432.CCR-07-0343.CrossRefPubMed De Heer P, De Bruin EC, Klein-Kranenbarg E: Caspase-3 activity predicts local recurrence in rectal cancer. Clin Cancer Res. 2007, 13: 5810-5815. 10.1158/1078-0432.CCR-07-0343.CrossRefPubMed
39.
go back to reference Contu PC, Contu SS, Moreira LF: BCl-2 expression in rectal cancer. Arq Gastroenterol. 2006, 43: 284-287. 10.1590/S0004-28032006000400008.CrossRefPubMed Contu PC, Contu SS, Moreira LF: BCl-2 expression in rectal cancer. Arq Gastroenterol. 2006, 43: 284-287. 10.1590/S0004-28032006000400008.CrossRefPubMed
40.
go back to reference Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990, 1: 99-106.PubMed Liotta LA, Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990, 1: 99-106.PubMed
41.
go back to reference De Clerk YA, Shimada H, Taylor SM, Langley KE: Matrix metalloproteinases and their inhibitors in tumor progression. Ann N Y Acad Sci. 1994, 732: 222-232. 10.1111/j.1749-6632.1994.tb24738.x.CrossRef De Clerk YA, Shimada H, Taylor SM, Langley KE: Matrix metalloproteinases and their inhibitors in tumor progression. Ann N Y Acad Sci. 1994, 732: 222-232. 10.1111/j.1749-6632.1994.tb24738.x.CrossRef
42.
go back to reference Unsal Kilic D, Uner A, Akyürek N, Erpolat P, Dursun A, Pak Y: Matrix metalloprotinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotheraphy. Int J Radiat Oncol. 2003, 33: 186-191. Unsal Kilic D, Uner A, Akyürek N, Erpolat P, Dursun A, Pak Y: Matrix metalloprotinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotheraphy. Int J Radiat Oncol. 2003, 33: 186-191.
43.
go back to reference Zhang C, Sheng ZY, Hu S, Gao JC, Yu S, Liu Y: The influence of apoptosis of mucosal epithelial cells on intestinal barrier integrity after scald in rats. Burns. 2002, 28: 731-737. 10.1016/S0305-4179(02)00210-3.CrossRefPubMed Zhang C, Sheng ZY, Hu S, Gao JC, Yu S, Liu Y: The influence of apoptosis of mucosal epithelial cells on intestinal barrier integrity after scald in rats. Burns. 2002, 28: 731-737. 10.1016/S0305-4179(02)00210-3.CrossRefPubMed
44.
go back to reference Wong MP, Cheung N, Yuen ST: Vascular endothelial GF is up-regulated in the early premalignant stage of colorectal tumor progression. Int J Cancer. 1999, 81: 845-850. 10.1002/(SICI)1097-0215(19990611)81:6<845::AID-IJC1>3.0.CO;2-5.CrossRefPubMed Wong MP, Cheung N, Yuen ST: Vascular endothelial GF is up-regulated in the early premalignant stage of colorectal tumor progression. Int J Cancer. 1999, 81: 845-850. 10.1002/(SICI)1097-0215(19990611)81:6<845::AID-IJC1>3.0.CO;2-5.CrossRefPubMed
45.
go back to reference Nozue M, Isaka N, Fukao K: Over-expression of vascular endothelial growth factors after preoperative radiation therapy for rectal cancer. Oncol Rep. 2001, 8: 1247-1249.PubMed Nozue M, Isaka N, Fukao K: Over-expression of vascular endothelial growth factors after preoperative radiation therapy for rectal cancer. Oncol Rep. 2001, 8: 1247-1249.PubMed
46.
go back to reference Zlobec I, Steele R, Compton CC: VEGF as a predictive marker of rectal tumor response to preoperative radiotheraphy. Cancer. 2005, 1104: 2517-2521.CrossRef Zlobec I, Steele R, Compton CC: VEGF as a predictive marker of rectal tumor response to preoperative radiotheraphy. Cancer. 2005, 1104: 2517-2521.CrossRef
Metadata
Title
Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation
Authors
Atilla Kurt
Fatih Yanar
Oktar Asoglu
Emre Balik
Vakur Olgac
Hasan Karanlik
Sevda Tanrikulu Kucuk
Evin Ademoglu
Gulcin Yegen
Dursun Bugra
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Clinical Pathology / Issue 1/2012
Electronic ISSN: 1472-6890
DOI
https://doi.org/10.1186/1472-6890-12-27

Other articles of this Issue 1/2012

BMC Clinical Pathology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine